REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Analysts at Leerink Partnrs boosted their FY2026 earnings per share estimates for shares of REGENXBIO in a research note issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.65) per share for the year, up from their prior estimate of ($1.69). The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.59) EPS and FY2029 earnings at ($1.76) EPS.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million for the quarter, compared to analyst estimates of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.
A number of other research firms have also recently issued reports on RGNX. Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research report on Tuesday, March 18th. The Goldman Sachs Group lowered their price target on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Wall Street Zen upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Chardan Capital reaffirmed a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a report on Thursday, March 20th. Finally, HC Wainwright lowered their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $31.63.
Read Our Latest Report on REGENXBIO
REGENXBIO Trading Down 3.2%
NASDAQ RGNX traded down $0.29 during trading on Friday, hitting $8.68. 830,369 shares of the company's stock were exchanged, compared to its average volume of 895,073. The stock's 50 day moving average price is $7.88 and its two-hundred day moving average price is $7.94. The company has a market cap of $435.39 million, a PE ratio of -1.73 and a beta of 1.11. REGENXBIO has a fifty-two week low of $5.04 and a fifty-two week high of $15.36.
Institutional Investors Weigh In On REGENXBIO
A number of institutional investors have recently made changes to their positions in the stock. FNY Investment Advisers LLC bought a new stake in REGENXBIO in the first quarter valued at approximately $35,000. Brooklyn Investment Group boosted its stake in shares of REGENXBIO by 163.7% in the 1st quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company's stock valued at $40,000 after purchasing an additional 3,466 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of REGENXBIO in the 4th quarter valued at $54,000. Pallas Capital Advisors LLC bought a new stake in shares of REGENXBIO in the 1st quarter valued at $74,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of REGENXBIO in the 4th quarter valued at $79,000. Institutional investors own 88.08% of the company's stock.
Insider Activity at REGENXBIO
In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $7.91, for a total value of $162,961.82. Following the sale, the director now owns 475,103 shares in the company, valued at approximately $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 12.79% of the stock is currently owned by company insiders.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
